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Abstract
Nanocarriers can deliver a wide variety of drugs, target them to sites of interest, and protect them from degradation and
inactivation by the body. They have the capacity to improve drug action and decrease undesirable systemic effects. We
have previously developed a well-defined non-toxic PEG-dendritic block telodendrimer for successful delivery of
chemotherapeutics agents and, in these studies, we apply this technology for therapeutic development in asthma. In these
proof-of-concept experiments, we hypothesized that dexamethasone contained in self-assembling nanoparticles (Dex-NP)
and delivered systemically would target the lung and decrease allergic lung inflammation and airways hyper-responsiveness
to a greater degree than equivalent doses of dexamethasone (Dex) alone. We found that ovalbumin (Ova)-exposed mice
treated with Dex-NP had significantly fewer total cells (2.7860.446105 (n = 18) vs. 5.9861.36105 (n = 13), P,0.05) and
eosinophils (1.0960.286105 (n = 18) vs. 2.9460.66105 (n = 12), p,0.05) in the lung lavage than Ova-exposed mice alone.
Also, lower levels of the inflammatory cytokines IL-4 (3.4361.2 (n = 11) vs. 8.5662.1 (n = 8) pg/ml, p,0.05) and MCP-1
(13.163.6 (n = 8) vs. 28.868.7 (n = 10) pg/ml, p,0.05) were found in lungs of the Dex-NP compared to control, and they
were not lower in the Dex alone group. In addition, respiratory system resistance was lower in the Dex-NP compared to the
other Ova-exposed groups suggesting a better therapeutic effect on airways hyperresponsiveness. Taken together, these
findings from early-stage drug development studies suggest that the encapsulation and protection of anti-inflammatory
agents such as corticosteroids in nanoparticle formulations can improve efficacy. Further development of novel drugs in
nanoparticles is warranted to explore potential treatments for chronic inflammatory diseases such as asthma.
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Introduction
Asthma is a progressive inflammatory airways disease that leads
to structural airway changes and debilitating symptoms in many
children and adults. An estimated twenty-six million people in the
United States have asthma, and for adults, asthma accounts for
two million emergency room visits per year. The annual cost for
asthma is nearly $15 billion in the U.S., and eighty percent of the
direct costs of asthma derive from the 5–10% of these patients who
have severe or difficult-to-control asthma [1–4]. Many of these
patients do not achieve asthma control with present therapies and
novel therapeutic agents with improved drug delivery systems are
needed.
We have focused on designing novel drug candidates to treat
allergic lower airways inflammation that is indicative of asthma. In
a prior study, we determined that by designing a specific T-shaped
PEGylated structure and attaching it to a a4b1 integrin inhibitor,
we could improve the anti-inflammatory properties of the inhibitor
in the lungs of mice [5]. In the present study, we addressed the
potential for using nanocarriers to improve drug delivery to the in
this same mouse model. Nanocarriers can deliver various types of
drugs, protect them from degradation and inactivation upon
administration, and increase the fraction of drug delivered to a
target organ. They can provide a mechanism to decrease the
undesirable systemic effects of drugs. Many nanoparticles have
been investigated for drug delivery, but only a few have been
approved by the FDA [6]. Professor Lam and colleagues
developed a well-defined nontoxic PEG-dendritic block teloden-
drimer composed of polyethylene glycol, cholic acid and lysine for
successful delivery of therapeutics [6]. The nanocarrier that we
chose to test has a greater loading capacity and superior stability
(longer than six months) than micelles reported in the literature [7]
The carrier allows for the delivery of slow-release hydrophobic
drug formulations, such as dexamethasone, directly to the lung. In
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these proof-of-concept experiments, we hypothesized that dexa-
methasone contained in protective, self-assembling nanoparticles
(Dex-NP) and delivered systemically would target the lung and
decrease allergic lung inflammation and airways hyper-respon-
siveness to a greater degree than equivalent doses of Dex alone.
Materials and Methods
Synthesis of Nanoparticle
Diamino polyethylene glycol (Boc-NH-PEG-NH2,
MW=2000 Da) was purchased from Rapp Polymere (Tu¨bingen,
Germany). Fmoc-D-Asp(Otbu)-OH, Fmoc-D-Lys(Boc)-OH, and
Fmoc-Lys(Fmoc)-OH were purchased from Anaspec, Inc. Hydro-
phobic NIRF dye DiD (1,10-dioctadecyl-3,3,30,30-tetramethylin-
dodicarbocyanine perchlorate, D-307), 49, 6-diamidino-2-pheny-
lindole (DAPI) and LysoTrackerH Green DND-2 were purchased
from Invitrogen. Dexamethasone, cholic acid, MTT [3-(4,5-
dimethyldiazol-2-yl)-2,5 diphenyl tetrazolium bromide], endocy-
tosis inhibitors including chlorpromazine hydrochloride, amiloride
hydrochloride hydrate, filipin III and all other chemicals were
purchased from Sigma-Aldrich (St. Louis, MO).
Boc-NH-PEG2k-CA4 telodendrimer (Fig. 1) was first synthe-
sized using Boc-NH-PEG-NH2 (MW, 2000 Da), lysine and cholic
acid as building blocks via solution phase condensation reactions
as described previously [6]. Briefly, Fmoc peptide chemistry was
used to couple Fmoc-Lys(Fmoc)-OH onto the unprotected amino
group of PEG for three rounds to generate a third generation of
dendritic polylysine. Cholic acid NHS ester was coupled to the
terminal end of dendritic polylysine, resulting in Boc-NH-PEG2k-
CA4 telodendrimer. Then, the Boc group on the PEG chain of the
telodendrimer was deprotected with 50% (v/v) trifluoroacetic acid
(TFA) in dichloromethane (DCM), and different number (n = 0, 1,
3 and 6) of Fmoc-D-Asp(Otbu)-OH (d) or Fmoc-D-Lys(Boc)-OH
(k) were subsequently conjugated to the distal end of PEG chain of
PEG5k-CA8 telodendrimer by using Fmoc peptide chemistry. The
primary amine at the N terminal of corresponding aspartic acids
or lysines conjugated PEG2k-CA4 telodendrimer was acetylated by
acetic anhydride. Finally, the Otbu groups of aspartic acids and
Boc groups of lysines were removed to generate PEG2k-CA4
telodendrimer with different number of free carboxylic acids and
primary amines, respectively. The telodendrimers were precipi-
tated and washed three times with cold ether, dialyzed against
water for 24 h and then lyophilized.
Characterization of the PEG2k-CA4 telodendrimer has been
described previously [8]. Briefly, the morphology and particle size
distribution of the telodendrimers loaded with the chemothera-
peutic drug doxorubicin were characterized by transmission
electron microscopy and direct light scatter techniques. The
particle sizes of drug -loaded PEG2k-CA4 micelles were in the
range of 10–20 nm in diameter and by electron microscopy, their
shapes were spherical with an average diameter of around 15 nm,
which was consistent with the results obtained from the light
scatter particle sizer. Cumulative drug release profiles measured in
dialysate showed that doxorubicin release from the PEG2k-
CA4telodendrimer increased slowly from 30% to 60% between
five to one hundred hours [8]. The characterization of this micelle
has not been repeated with dexamethasone in these experiments.
Animals
Mice (Balb/c, adult 8–12 wk. old males) were purchased from
Charles River or Jackson Laboratories. Mice were certified as
chronic respiratory disease free by the supplier, and are routinely
screened for health status by serology and histology by our
veterinary animal resources facility. There were no paramyxoviral,
or other viral pathogens, present in these animals that might
themselves provoke chronic airway inflammation. Animals were
maintained in a HEPA-filtered laminar flow cage rack with a 12-
hour light/dark cycle and allowed free access to food and water.
Animals were housed and cared for by the veterinary staff of
Animal Resource Services at University of California, Davis
(UCD) in AALAC- accredited facilities, in plastic cages over
autoclaved bedding in HEPA-filtered cage racks. Food (Purina
Rodent Chow) and water are provided ad libitum. The mouse
protocol and procedures were approved by the University of
California, Davis Institutional Animal Care and Use Committee.
In order to ensure animal comfort, mice were administered deeply
sedating doses of medetomidine and tiletamine/zolpidem for non-
terminal procedures, and lethal doses of pentobarbital at the time
of euthanasia.
Exposure of Mice to Ovalbumin Aerosol
Mice were divided into three air-exposed and three Ova-
exposed treatment groups which varied in treatment by drug
intervention only as described below. We developed an aerosol
exposure apparatus suitable for exposure of mice to Ova aerosol
after prior sensitization by i.p. injection of ovalbumin. Sensitiza-
tion to Ova was developed by intraperitoneal injections on days 0
and 14 of chicken egg albumin (10 mg/0.1 mL ovalbumin, grade
V, $98% pure, Sigma, St. Louis, MO) with alum as an adjuvant
[9]. Exposure to Ova aerosol was performed using chambers and
generators as described previously [10]. Aerosol exposures began
on day 28. Mice were exposed for 30 minutes, three times per
week for the duration of the experiment. Age-matched mice were
exposed aerosols derived from 10 ml phosphate buffered saline,
(pH 7.4, PBS), to 10 mL ovalbumin in PBS (10 mg/ml) or to
filtered air. A side-stream nebulizer (Invacare Corporation, Elyria,
OH), ProNeb compressor nebulizer (Pari, Richmond, VA), and
Passport Compressor (Invacare, Sanford, FL) were used to
generate the aerosols.
Figure 1. Diagram of PEG2k-CA4 telodendrimer. Boc-NH-PEG2k-
CA4 telodendrimer was first synthesized using Boc-NH-PEG-NH2 (MW,
2000 Da), lysine and cholic acid as building blocks via solution phase
condensation reactions. Fmoc peptide chemistry was used to couple
Fmoc-Lys(Fmoc)-OH onto the unprotected amino group of PEG for
three rounds to generate a third generation of dendritic polylysine.
doi:10.1371/journal.pone.0077730.g001
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In our initial experiment, we determined that the size and shape
of the PEGylated dendrimer did not affect dexamethasone-
mediated response. Specifically, there was no difference in the
anti-inflammatory effect of dexamethasone whether it was loaded
in a PEG2k-CA4 or a PEG
5k-CA8 telodendrimer. All subsequent
experiments were performed with the PEG2k-CA4 telodendrimer.
Thus, mice were administered either Dex-PEG2k-CA4 (Dex-NP;
5 mg/kg/day of Dex), the equivalent dose of Dex, or PEG2k-CA4
(NP) alone thirty minutes before exposure to either ovalbumin or
filtered air for 7 days (3 ovalbumin exposures). The decision to use
the intravenous route of administration with the PEGylated
formulation was made after a consideration of the pharmacology
of the newly synthesized antagonists, to address concerns that
absorption of the larger PEGylated antagonists from a bolus dose
i.p. might be impaired. Lung tissue and lavage samples were
measured in all mice. To address the question of whether the
PEG2k-CA4 affected lung cell counts caused hemolysis of red blood
cells as earlier reported [6], we administered the nanoparticle
compound in its empty formulation in animals prior to either
filtered air or Ova.
Lung Compliance and Resistance Measurements
We measured dynamic compliance and resistance of the
respiratory system with a plethysmograph for restrained animals.
(Buxco Inc., Troy, NY). Mice were deeply anesthetized and
sedated with medetomidine, 0.5 mg/kg (Domitor, Orion Pharma,
Finland), and tiletamine/zolpidem, 50 mg/kg (Telazol, Fort
Dodge Laboratories, Fort Dodge, IA) and surgically cannulated.
Mice were then inserted into the whole body plethysmograph and
ventilated at 7–8 cc/kg with a mouse ventilator (MiniVent,
Harvard Apparatus, Cambridge, MA) for the duration of the
procedure. Compliance and resistance measurements were made
at baseline and immediately following serial 3-minute nebuliza-
tions of saline and serial low doses of methacholine (0.5, 1.0 and
2.0 mg/ml).
Measurement of Exhaled NO and Nitrate/Nitrite
A 5-minute sample of exhaled gases from the exhalation port of
the ventilator was collected immediately after insertion of a mouse
into the plethysmograph. Samples were collected into a specially
constructed Tyvek bag from the cannulated mice. This 5-minute
sample is adequate for the measurement of NO concentration in
the expired air, using a Sievers Nitric Oxide analyzer (Sievers Inst.,
Boulder, CO) [11].
Whole Lung Lavage
Mice were killed with an overdose of pentobarbital/dilantin one
hour after cessation of the last aerosol exposure, their tracheas
were cannulated, and their lungs were lavaged twice with 1 ml
portions of phosphate-buffered saline, pH 7.4. The total volume of
lavage fluid recovered averaged .80%. Collected lavage fluid was
centrifuged in a bench top unit at 1200 rpm for 10 min and the
resulting pellet was again suspended in 0.5 ml PBS. The final cell
suspension was used to determine total lavaged cell number using
a hemacytometer and calculate cell differentials using cytocen-
trifuge preparations. Aliquots (100 ml) of the cell suspension
processed onto glass slides in a cytocentrifuge (1650 rpm for 15
minutes) Slides were then stained with Diff-Quick staining kit
(International Reagent Corp, Kobe, Japan). Stained cells were
classified as pulmonary alveolar macrophages, polymorphonuclear
leukocytes (neutrophils), lymphocytes, or ‘‘other’’ based upon
staining color and characteristic morphology. Blood smears were
made to quantify the number of schistocytes and acanthocytes in
the peripheral blood of animals. Results are presented as pooled
data from the two independent experiments, which gave similar
independent results.
Lung Isolation and Fixation
After lung lavage, the lungs were fixed for histological
evaluation at 30 cm pressure with 1% paraformaldehyde for at
least 24 hours, then either processed for light microscopy in
paraffin or stored in 70% ethanol for dissection and analysis of
airways. Other lung preparations were dissected without fixation
to prepare airways, which were frozen and stored at –80uC until
used for extraction of RNA for PCR analysis.
Tissue Staining
After 1 hour of in situ fixation, the lung removed from the body
cavity, placed in 70% ethanol and prepared for paraffin
embedding in a standard fashion. Lung sections of 5 mm thickness
were made with special attention to cutting through the larger
lobar bronchi in parallel. Sections were baked at 37uC overnight
prior to staining. Lung sections were stained with Alcian Blue-
Periodic Acid-Schiff (PAS) and counterstained with hematoxylin
and eosin.
Lactate Dehydrogenase (LDH) and Bilirubin Assay
Commercially available colorimetric kits were purchased to
perform LDH activity and bilirubin measurements in plasma.
These assays were used as indirect measures of intravascular
hemolysis. Blood was drawn by cardiac puncture and centrifuged
in K2 EDTA Plus blood collection tubes at 1200 rpm for 12
minutes. Plasma was aliquoted into 60 ml aliquots and stored,
protected from light at 4uC until further use. LDH activity was
determined in 2 ml plasma using the Lactate Dehydrogenase
Activity Assay (Sigma-Aldrich, St. Louis, MO) as per manufac-
turer’s instructions using colorimetric detection at 450 nm.
Bilirubin concentration in 50 ml plasma was determined using
the Quantichrom Bilirubin Assay Kit (Bioassay Systems, Hayward,
CA) as per manufacturer’s instructions. Assay measures the
reaction of bilirubin with diazotized sulfanilic acid producing a
red product that was measured at 540 nm. Caffeine benzoate was
added to separate bilirubin from the unconjugated bilirubin
protein complex to measure total plasma bilirubin.
Cytokine and Chemokine Assay
The concentrations of selected Th1 and Th2 cytokines and
chemokines from BALF supernatant were measured using
commercially available multiplex assays (Millipore, St. Charles,
MO, USA). For cytokine/chemokine sample measurements below
the lower detection limit, results were assigned a value equal to the
minimum detection limit for the specific assay to facilitate
statistical analysis of the data.
Statistical Analysis
Results are presented as mean values 6 SEM. Means were
compared by unpaired Student’s t-test or ANOVA (1-way or 2-
way), with Tukey’s or Bonferroni correction for multiple
comparisons applied where appropriate, using the Prism 5
software package (Graphpad, Inc., San Diego, CA). A p-value of
0.05 or less was taken to indicate statistical significance. Values
that differed by more than two standard deviations from the mean
were excluded from the statistical analysis. GraphPad Software
(San Diego, CA) was used for data analysis. For parametric
analysis of data, a t-test with appropriate correction for multiple
comparisons and unequal standard deviations between groups was
used. For non-parametric analysis, a Wilcoxin test was used.
Nanoparticle Steroids in Asthma
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Results
In a series of three separate experiments, Balb/c mice were
exposed to inhaled ovalbumin or to filtered air three times over
seven days and treated with either 5 mg/kg of Dex, 5 mg/kg of
Dex loaded in -PEG2k-CA4 nanoparticles (Dex-NP), or empty
nanoparticles (NP) intravenously thirty minutes before each of the
three exposures. None of the mice had any gross observable
toxicity related to the nanoparticle compound and the lung
appears normal. There was not an increase in schistocytes on
peripheral blood smears in the empty nanoparticle formulation
treated animals, which had been a prior concern [12]. However,
LDH activity was significantly higher in the plasma of the empty
nanoparticle (NP) treated animals (374.2698.9 milliunits/ml)
compared to either the PBS control (147.3649.65 milliunits/ml)
or Dex-NP treated animal (191.1666.2 milliunits/ml, p,0.01 by
one-way ANOVA, Fig. 2). There was a trend to increased direct
bilirubin in both NP treated groups (1.660.3 mg/dl (PBS) vs.
10.966.5 mg/dl (NP) vs. 7.066.4 (Dex-NP), but these differences
were not statistically significant (n = 4/group, p = 0.09 by 1-way
ANOVA). Furthermore, there was no difference between the PBS
and NP groups by student’s t-test (1.6+/20.3 vs. 10.9+/26.5
respectively, p= 0.20). While there were no significant differences
in plasma bilirubin content among the groups, we believe this
assay was compromised by the turbidity of the plasma in all NP
and Dex-NP treated animals which may be complicated the
interpretation of the bilirubin readings difficult. Turbidity of the
plasma was not an issue in the highly sensitive LDH assay which
could be diluted substantially.
Effects of Ovalbumin Exposure on Lung Inflammatory
Response
In all mice sensitized and exposed to ovalbumin, we observed a
significant increase in the numbers of inflammatory cells recovered
by lung lavage compared to mice exposed to filtered air alone,
consistent with prior studies from our lab [13–15]. (Fig. 3). The
number of lung lavage cells from the groups of mice exposed to
filtered air from all time points evaluated was 8.2160.86104 cells
(pooled data from all groups, n= 41). The normal lung lavage
from a healthy mouse contains more than 95% alveolar
macrophages and our observations were consistent with this
finding. There was a significant increase in the number of total
lung lavage cells in each of the four ovalbumin exposed groups
compared to the corresponding air-exposed animals. Ova-exposed
mice treated with Dex-NP(Ova Dex-NP) had significantly fewer
total cells in the lung lavage than Ova-exposed mice (Ova PBS)
alone (2.7860.446105 (n= 18) vs. 5.9861.36105 (n= 13) respec-
tively, P= 0.013). While the Dex alone treated group (Ova Dex)
did demonstrate an expected trend towards decreased cell counts
(3.59610.76105 (n = 13)) compared to the Ova PBS control
group, this was not statistically significant. Furthermore, Ova-
exposed mice treated with empty NP treated animals (Ova NP) did
not have fewer inflammatory cells in their lung lavage fluid than
the Ova PBS controls.
Similarly, lung lavage eosinophil counts were significantly lower
in the Ova Dex-NP animals. Ova Dex-NP mice versus Ova PBS
control mice had 1.0960.286105 (n= 18) vs. 2.9460.66105
(n= 12) respectively, P= 0.016, Fig. 4). While the Ova Dex
treated group did demonstrate an expected trend towards
decreased eosinophil cell counts compared to the PBS-treated
control group, again this was not statistically significant. There
were no significant differences in the numbers of lymphocytes or
neutrophils in the BALF among the groups. Collectively, these
results suggest strongly that intravenous Dex-NP is more
efficacious in preventing eosinophilic or allergic lung inflammation
than the equivalent dose of Dex alone in Ova-exposed mice using
this model.
Respiratory System Resistance and Compliance
Since airway hyper-responsiveness (AHR) is a fundamental
feature of asthma, we compared the total lung resistance and
dynamic compliance at baseline and after inhalation of metha-
choline in mice after the final ovalbumin exposure. Statistical
Figure 2. LDH activity was determined by a lactate dehydro-
genase activity assay (Sigma-Aldrich, St. Louis, MO) as per
manufacturer’s instructions using colorimetric detection at
450 nm. In this experiment, animals were not sensitized or exposed to
ovalbumin. LDH activity was significantly higher in the plasma of the
empty nanoparticle (NP) treated animals (374.2698.9 milliunits/ml)
compared to either the PBS control (147.3649.65 milliunits/ml) or Dex-
NP treated animal (191.1666.2 milliunits/ml, p,0.01 by one-way
ANOVA).
doi:10.1371/journal.pone.0077730.g002
Figure 3. Total cells recovered by lung lavage from Balb/c mice
exposed to filtered air or Ova aerosol for 1 week. Of the filtered
air exposed mice, the mean cells present in their lavage was
8.2160.86104 cells (pooled data from all groups, n = 41). There was a
significant increase in the number of total lung lavage cells in each of
the four ovalbumin exposed groups compared to the corresponding
air-exposed animals (p,0.01 compared to all Ova groups). Ova-exposed
mice treated with Dex-NP had significantly fewer total cells in the lung
lavage than Ova-exposed mice (PBS-treated) alone (2.7860.446105
(n = 18) vs. 5.9861.36105 (n = 13) respectively, P = 0.013). Data are
presented as mean values6SEM. *denotes p,0.05 and analyzed by
Student’s T-test.
doi:10.1371/journal.pone.0077730.g003
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comparisons were made to determine the effect of Dex and the
nanoparticle status on resistance and compliance at baseline, after
inhalation of aerosolized saline (vehicle), and serial low doses of
aerosolized methacholine (0.5, 1.0 and 2.0 mg/mL). Data from all
eight treatment groups were analyzed simultaneously using 2-way
ANOVA with Bonferroni correction for multiple comparisons.
There was evidence of a significant interaction among the groups
(p,0.0001) when analyzed collectively. Inhalational challenge
with OVA increased Rrs and AHR above air controls in response
to methacholine (MCh) at 2 mg/mL indicating an adequate
airway response to Ova in our model #p,0.0001). In the OVA
group, treatment with either Ova Dex or its nanoparticle drug
vehicle (Ova NP) independently attenuated Rrs and AHR
(Fig. 5*,**p,0.0001) down to air control levels at the highest
dose of methacholine. (Fig. 6). Rrs was significantly lower in the
Ova Dex-NP compared to the Ova Dex treated animals when
analyzed by linear regression (F= 2.57, P,0.05), which supports
the notion that it was more efficacious in preventing the both the
inflammatory and AHR changes typically seen in this model.
While AHR is the hallmark of the physiological changes in this
mouse model, we also examined the effect of ovalbumin and the
treatment on total dynamic compliance (Cdyn) of the respiratory
system.
There were no differences in Cdyn among groups of mice
exposed to either air or Ova. This finding suggests that the lung
inflammation and injury were not the primary determinants of the
physiological changes seen with the resistance measurements.
Lung lavage Cytokines
We examined several Th1 and Th2 cytokines in lung lavage
fluid to determine whether dexamethasone containing nanopar-
ticles affected the production of mediators important in allergic
asthma. In OVA-challenged animals, Dex-NP(Ova Dex-NP)
significantly decreased the lung lavage content of IL-4 compared
to Ova PBS controls (3.4361.2 (n = 11) vs. 8.5662.1 (n = 8) pg/
ml, p,0.05) (Fig. 7), while Dex alone (Ova Dex) did not. IL-13
levels in lung lavage fluid were significantly decreased in only the
Dex treated animals compared to the Ova control animals.
Neither BALF IL-4 levels (3.461.2 vs. 5.162.9 pg/ml, p = 0.6)
nor BALF IL-13 levels (44.367.3 (n = 10) vs. 61.1610.9 (n = 5)
pg/ml, p = 0.2) were lower in the Ova Dex-NP animals compared
to the Ova-NP animals. Furthermore, BALF IL-4 levels were not
lower in the Ova-NP animals compared to the Ova animals
(5.166.5 (n = 5) vs. 8.5662.1 (n = 8) pg/ml, p= 0.12), while the
Ova Dex-NP animals did have lower IL-4 levels than the Ova
animals. Similarly, BALF IL-13 levels were not lower in the
Ova+NP animals compared to the Ova animals (61.1610.9 (n = 5)
vs. 99.9636.6 (n = 8) pg/ml, p = 0.7), while the Ova Dex-NP
animals did have lower IL-13 levels than the Ova animals. We
believe that the primary reason that there were no differences
found in these two inflammatory cytokines between the Ova Dex-
NP and Ova-NP was the few animals included in the Ova-NP
group. Given the variability in these assay read-outs, many more
animals would need to be included to determine the presence or
lack thereof of an anti-inflammatory effect of empty nanoparticles.
Furthermore, MCP-1 was significantly lower in the Ova Dex-
NP treated animals compared to the Ova PBS control-treated
animals (13.163.6 (n = 8) vs. 28.868.7 (n = 10) pg/ml, p,0.05).
Ova Dex treated animals were not significantly different from the
Ova PBS control group. For IP-10, both the Ova Dex
(118618.3 pg/ml) and the Ova Dex-NP (145.8625.8 pg/ml)
had lower concentrations in lung lavage fluid than the Ova control
animals (292.2654.8 pg/ml, p,0.05 for both). Neither Dex nor
Dex-NP had any significant effect on BALF concentrations of
eotaxin, IL-5, IL-6, IL-1a, IL-9, IL-10, IL-12, IL-17, or IFN-g,
TNF, GM-CSF, MIP-1a, KC, IP-10, RANTES.
Exhaled Nitric Oxide
There was a significant increase in FeNO (14.6161.4 ppb) at 2
weeks only in the filtered air exposed mice treated with Dex-NP
(FA Dex-NP) compared to the other groups (1-way ANOVA,
p,0.05, data not shown). There were no other significant
differences. We conclude exhaled nitric oxide did not correlate
with the level of eosinophilic lung inflammation, which differs
from what has been described in humans [16].
Goblet Cell Hyperplasia
To assess the effect of the nanoparticles containing dexameth-
asone on aspects of lung remodeling, we quantified goblet cell
numbers by counting PAS positive stained cells. The total number
of PAS stained cells were quantified in the generation airway
immediately branching from the lobar bronchus. PAS cells were
counted per 100 basal airway epithelial cell nuclei. The number of
positive PAS stained cells was significantly lower in the Ova Dex-
NP group than either the Ova Dex (47.866.8 (n = 4) vs. 85.562.7
(n = 4) respectively, p,0.05, Fig. 8, Fig. 9a–d) or the Ova PBS
control group (47.866.8 (n = 4) vs. 79.062.8 (n = 4), p,0.05).
Only two of the Dex-NP animals had sections fixed for staining
and we cannot determine statistically whether there are fewer PAS
positive cells in the airway epithelium compared to the Ova+Dex-
NP animals. This reduction in goblet cell metaplasia in the Ova
Dex-NP animals is consistent with the reduced inflammatory cell
burden seen in these animals. Particularly, the lower IL-4 levels in
the Ova Dex-NP may be responsible for the observed effect seen in
the mucous cell amounts. While mucus extruded into the airway
lumen was not quantified, it grossly appeared less in the Ova Dex-
NP group by histology.
Discussion
One hallmark of asthma is chronic allergic airway inflammation
that is dominated by the effector leukocytes eosinophils, mast cells,
and Th2 lymphocytes. Corticosteroids, particularly inhaled
Figure 4. Total eosinophils recovered by lung lavage from
Balb/c mice exposed to Ova aerosol for 1 week. Eosinophils
comprised a significant proportion of the cells present in the lavage of
mice exposed to Ova. Ova-exposed mice treated with Dex-NP had fewer
eosinophils compared to PBS control mice (1.0960.286105 (n = 18) vs.
2.9460.66105 (n = 12) respectively, P = 0.016). Data are presented as
mean values6SEM. *denotes p,0.05 by Student’s T-test.
doi:10.1371/journal.pone.0077730.g004
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corticosteroids, are the standard of care for treating asthma and
they are the basis of all treatment guidelines. Not surprisingly, in
the Ova exposure mouse model, pretreatment with corticosteroids
like dexamethasone leads to fewer lung lavage eosinophils than in
mice treated with placebo. [17,18] In the proof-of-concept
experiments described here, we opted to use the corticosteroid
dexamethasone. To address the issue of bioavailability of a
hydrophobic corticosteroid like dexamethasone, we hypothesized
that a pegylated, protected, and self-assembling nanoparticle
would be more efficacious in preserving the function of these
particles. The rationale was that a pegylated compound would
remain in the blood circulation longer than the non-PEGylated
formulations and that the nanoparticle would protect and release
the dexamethasone in a time delayed response. Therefore, we
expected that drug effect would be greater.
We can summarize our results as such; mice exposed to Ova
and pretreated with dexamethasone encapsulated in self-assem-
bling nanoparticles had less lung inflammatory cells and lower
cytokine levels than mice treated with equivalent doses of
dexamethasone alone. Furthermore, the Dex-NP treated animals
had lower lung resistance when challenged with methacholine and
less structural airway changes. Collectively, the results show a
Figure 5. Total respiratory system resistance in Balb/mice exposed to either filtered air or 1 week of Ova (a) or Ova alone (b).
Statistical comparisons were made to determine the effect of Dex and the nanoparticle status on resistance and compliance at baseline and after
inhalation of saline (vehicle) and serial low doses of methacholine (0.5, 1.0 and 2.0 mg/mL). In the OVA group, treatment with either Dex or its
nanoparticle drug vehicle (NP) independently attenuated Rrs and AHR (*,**p,0.0001) down to air control levels at the highest dose of methacholine.
Rrs was significantly lower in the Dex-NP treated animals across all time points (F = 2.57, P,0.05), which supports the notion that it was more
efficacious in preventing the both the inflammatory and AHR changes typically seen in this model. Data from all eight treatment groups were
analyzed simultaneously using 2-way ANOVA with Bonferroni correction for multiple comparisons.
doi:10.1371/journal.pone.0077730.g005
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better treatment response with the dexamethasone when it was
contained within our unique self-assembling nanoparticles.
The inflammation of asthma is a Th2 lymphocyte mediated
process. The Th2 cytokines IL-4 and IL-13 are critical to the
initiation and potentiation of the airway inflammation and drivers
of the remodeling response including mucous production, smooth
muscle cell hypertrophy and epithelial cell proliferation. Both IL-4
and IL-13, and particularly in combination, are active targets for
future therapies, though the IL-4 clinical trials were unpromising
in the past [19–21]. In the Ova exposure mouse model, we would
expect to see decreased production and secretion of these
characteristic cytokines more so than non-specific inflammatory
cytokines such as IL-6, TNF-a, and GM-CSF. Our lung lavage
cytokine results are consistent with this notion as we found that IL-
4 and IL-13 were significantly lower in the Ova Dex-NP treated
mice compared to the Ova PBS control animals. There were no
significant differences among the Ova treated groups in the
discussed non-specific inflammatory cytokines. Interestingly, while
IL-13 levels were lower in both Ova Dex and Ova Dex-NP treated
groups compared to the Ova PBS controls, IL-4 was lower in the
Ova Dex-NP animals only. IL-4 is a key cytokine in allergic
inflammation and asthma. Not only does IL-4 stimulate isotype
switching of B lymphocytes and IgE production, but it plays an
important role in the recruitment of mast cells to the airway and
endothelial vascular cell adhesion molecule-1 (VCAM-1) expres-
sion [22], which is critical to the migration of eosinophils and other
leukocytes to the airway. IL-13, in turn, signals airway epithelial,
goblet and smooth muscle cell changes that define the chronic
remodeling response [17,23,24]. Our data is consistent with a
pronounced suppression of Th2 lymphocyte mediated inflamma-
tion and airway remodeling.
Figure 6. Total lung compliance in mice exposed to either filtered air or 2 weeks of OVA (a) or Ova alone (b). Lung compliance was
measured at baseline and following serial doses (0, 0.5, 1.0 and 2.0 mg/ml) of nebulized methacholine (MCh). There was no difference in the slope of
the MCh response among any of the groups of mice. Data from all eight treatment groups were analyzed simultaneously using 2-way ANOVA with
Bonferroni correction for multiple comparisons.
doi:10.1371/journal.pone.0077730.g006
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It is intriguing to hypothesize that the nanoparticle-protected
dexamethasone enabled a more potent Th2 lymphocyte inhibitory
effect, perhaps through better lung deposition and the delayed
release of drug. Furthermore, the potential to improve the
nanoparticle formulation by adding a ligand that would increase
the specificity towards lymphocytes, for example, would be
appealing. The need to deliver drugs to target organs in a specific
and efficient manner, at the lowest dose achievable, has allowed
for the innovation of nanoparticles and nanocarriers of diverse
properties. Lipid or hydrophobic nanocarriers have been devel-
oped which allow the delivery and deployment of hydrophobic
drugs to target tissues, at lower doses and with higher efficacy. This
would be possible with the addition of compound such as LLP2A,
a high affinity a4b1 integrin antagonist that we have previously
tested in this model [5], possibly for inhaled therapy.
In the field of cancer therapy, lipid nanocapsules appear as
promising vehicles for the delivery of hydrophobic drugs such as
docetaxel [25]. Docetaxel-loaded nanocapsules had earlier cancer
anti-proliferative effects and apoptosis in MCF-7 breast cancer
cells. Transfer of this technology to benign, chronic diseases like
asthma has been slow, partly because of concerns with long term
toxicities; however, there are some recent precedents with
nanomicelles. Nanomicelles have been developed to carry various
agents including beclomethasone dipropionate (BDP), as a carrier
for delivery to the lungs. These phospholipid nanomicelles
enhanced corticosteroid solubility by 1300 times its actual
solubility, slowed down the release of drug, and demonstrated
significant lung deposition [26]. The advantage of this system was
the delivery of poorly soluble corticosteroids via nebulization while
improving drug deposition. In another study, BDP in self-
assembling pegylated phospholipid micelle for lung delivery
showed excellent biocompatibility of both empty and drug-loaded
systems when evaluated in human bronchial epithelial cells and
erythrocytes [27]. In asthma, the potential to increase the potency
of steroids in the lung in a safe and efficient manner, while
lowering the total concentration delivered would be a significant
step forward.
Concern regarding drug toxicity remains a major barrier to
treatment and the expectation is that targeting encapsulated drug
can minimize these toxicities. Nanoparticle delivery systems
including micelles, liposomes, solid lipid nanoparticles, nanoemul-
sions, and nanosuspensions [28] are composed of physiological
lipids and they are generally well-tolerated the human body.
Despite this advantage, direct nanoparticle toxicity is a concern
particularly for inhaled formulations which would be of interest in
lung diseases like asthma. For example, the PEG2k-CA4 teloden-
drimer that we designed would never be administered as a blank,
unloaded construct given the concerns with hemolysis, concerns
that were previously identified in in vitro studies [6]. In our
present asthma modeling studies, there is again enough correlative
data with the LDH assay to raise this concern. LDH activity was
significantly higher in the plasma of the empty nanoparticle (NP)
treated animals compared to either the PBS control or Dex-NP
treated animals. There were no significant differences in plasma
bilirubin content among the groups, but this assay was compli-
cated by the turbidity of the plasma in all NP and Dex-NP treated
animals, which made the interpretation of the bilirubin readings
difficult. Turbidity of the plasma was not an issue in the highly
Figure 7. Lung lavage concentrations of IL-4 and IL-13 in mice
exposed to air and Ova (a and b). In OVA-challenged animals, Dex-
NP significantly decreased the lung lavage content of IL-4 compared to
PBS control (3.4361.2 (n = 11) vs. 8.5662.1 (n = 8) pg/ml, p,0.05), while
Dex alone did not. IL-13 levels in lung lavage fluid were significantly
decreased in only the Dex treated animals compared to the Ova control
animals. Data are presented as mean values6SEM. *denotes p,0.05 by
Student’s T-test.
doi:10.1371/journal.pone.0077730.g007
Figure 8. Number of PAS positive cells present in the airway
epithelium among groups of mice exposed to Ova. PAS staining
of 5 mm-thick, left lobe lung sections from select mice in each
experimental group and images and counting of cells was done at
4006magnification. Filtered air exposed mice displayed an average of
,1% PAS positive cells in the airway epithelium. The total number of
PAS stained cells were quantified in the generation airway immediately
branching from the lobar bronchus. PAS cells were counted per 100
basal airway epithelial cell nuclei. The number of positive PAS stained
cells was significantly lower in the Dex-NP group than either the Dex
(47.866.8 (n = 4) vs. 85.562.7 (n = 4) respectively, p,0.05, Fig. 6) or the
control group (47.866.8 (n = 4) vs. 79.062.8 (n = 4), p,0.05) among the
Ova exposed groups. Data are presented as mean values6SEM.
*denotes p,0.05 by Student’s T-test.
doi:10.1371/journal.pone.0077730.g008
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sensitive LDH assay. Overall, the results of increased plasma LDH
in the empty NP treated animals is consistent with prior in vitro
studies by our group and suggest that empty NP can cause
hemolysis. This is not apparent in drug-loaded Dex-NP constructs.
Taken together, drug loaded nanoparticles appear to ameliorate
any potential for these carriers to trigger intravascular hemolysis.
We believe that further safety and efficacy studies for consideration
of a new Investigational New Drug application with this
nanoparticle should continue but only with drug-loaded con-
structs. Hemolysis will be the safety concern that we will focus
upon in future in vivo studies.
Outside of our findings, two important questions have been
raised. Do these submicron particles penetrate the lung paren-
chyma and causes systemic injury, as is seen with asbestos and
other particulate exposure? Two, does the body’s adaptive
immune system generate an adverse response to nanoparticles
over time? Recent studies investigating lung and systemic effects
have used metal (titanium, zinc, silver) and silica containing
Figure 9. PAS staining for goblet cells from representative sections of lobar bronchi or daughter generation airway in mice from a)
air-exposed, b) Ova-exposed (Ova), c) Ova-exposed Dex-treated (Dex), d) Ova-exposed Dex-nanoparticle (Dex NP), and e) Ova-
exposed nanoparticle (NP) treated mice. Lung sections were stained with Alcian Blue-Periodic Acid-Schiff (PAS) and counterstained with
hematoxylin and eosin and photographed at 4006magnification. PAS positive cells in airways were fewer in Dex NP treated animals.
doi:10.1371/journal.pone.0077730.g009
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nanoparticles [29,30]. While systemic absorption is found with
these heavy metal containing agents, the long term effects are
unclear.
Perhaps a better comparator would be inhaled environmental
particulate matter (PM) exposure in the 2.5–10 mm range; decades
of studies have unraveled the time course for inflammatory cell
recruitment and activation in the lung. Taken together, these
studies show that acute particulate exposure leads to a transient
loss of lung macrophages and adverse effects on macrophage
function in the first 24 to 48 hours. For example, intra-tracheal
instillation of ambient London PM10 into rats causes a decrease in
macrophage numbers at 18 hours [31], a reduced macrophage
migration response to zymogen-activated serum, and less phago-
cytic potential. Similarly, impaired alveolar macrophage chemo-
taxis has been observed after exposure to titanium oxide particles
[32]. The reduction in macrophage numbers in lung lavage fluid
appears to be maximal about six to twelve hours after exposure to
PM2.5–10 in mice followed by a gradual recovery to baseline
macrophage numbers by 18 to 24 hours [33]. The mechanism of
acute toxicity of particulates on alveolar macrophage cells is not
fully understood. Franzi and colleagues found a direct toxic effect
of California wildfire PM on RAW264.7 cells, a murine
macrophage cell line [34] that appeared to be mediated by
oxidative damage. This notion is further supported by work by
Chirino and colleagues who found a greater than 50% reduction
in glutathione production in A549 lung epithelial cells exposed to
PM10 from Mexico city [35]. Recovery from the initial adverse
effects of particulate exposure on lung macrophage function
requires the release and recruitment of bone-marrow derived
macrophages. Taken together, we can surmise that upon exposure
to environmental particulates, lung macrophages undergo a series
of functional changes that critically impair their ability to clear
particulates from the lung in the initial 24 to 48 hours. We can
hypothesize that heavy metal based nanoparticles affect macro-
phages similarly, but further studies in this area are clearly
warranted.
Several limitations to our study are apparent. First, we did not
measure the pharmacokinetics of either the dexamethasone or the
PEGylated nanoparticle compound in the mouse to determine
optimal dosing. However, we believe that the magnitude of the
anti-inflammatory effect of the compounds seen at the dosing
interval chosen demonstrates efficacy. Second, we did not confirm
the deposition of the synthesized compounds in the lung by in vivo
imaging; however, we have shown previously that dye-labeled
nanomicelles can be imaged in subcutaneous xenografts of tumors
[36]. Third, the number of animals that were tested was small. We
invested significant effort in assuring the purity of each nanopar-
ticle protected drug and were constrained by the limited amount of
these antagonists in each experiment. In this regard, these
experiments should be considered early-stage development. Lastly,
we did not design our study to be able to detect a potential anti-
inflammatory effect of the empty nanoparticle alone. We were
concerned about the potential for intravascular hemolysis and
animal welfare. Given this, we performed only a single experiment
of i.v. empty nanoparticles in a few animals. We cannot compare
the independent effect of the empty nanoparticles and therefore
cannot discount a contributing anti-inflammatory effect in mice
exposed to ovalbumin.
Conclusions
To summarize, we found that mice pretreated with dexameth-
asone encapsulated in self-assembling nanoparticles had less
allergic lung inflammatory cells and lower inflammatory cytokine
levels than mice treated with equivalent doses of dexamethasone
alone. Furthermore, the Dex NP treated animals had better total
lung resistance when challenged with methacholine and less of the
structural airway changes that are seen with chronic airway
remodeling. Collectively, the results show a better treatment
response with the dexamethasone when it was contained in our
unique self-assembling nanoparticles. However, it is important to
note toxicity must be evaluated further if this work is to lead to
clinical studies.
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